Thr325Ile polymorphism of the TAFI gene is related to TAFI antigen plasma levels and angiographic restenosis after percutaneous coronary interventions

Thrombosis Research

Volumn 114, Issue 2, 2004, Pages 137-141

  Segev, Amit ^a   Hegele, Robert A ^b   Lau, Herbert K ^a   Sparkes, John D ^a   Teitel, Jerome M ^a   Chisholm, Robert J ^a   Strauss, Bradley H ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

Polymorphism; Restenosis; TAFI; Thrombosis

Indexed keywords

ANTIGEN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTERY LESION; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CONTROLLED STUDY; CORONARY ARTERY; CORONARY STENT; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RESTENOSIS; STABLE ANGINA PECTORIS; STATISTICAL SIGNIFICANCE; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIGENS; BIOLOGICAL MARKERS; CANADA; CARBOXYPEPTIDASE U; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; GRAFT OCCLUSION, VASCULAR; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION;

EID: 4043166189     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2004.06.003     Document Type: Article

References (23)

1. Schwartz R.S., Murphy J.G., Edwards W.D., Camrud A.R., Vliestra R.E., Holmes D.R. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation. 82:1990;2190-2200
2. Hendriks D., Scharpe S., van Sande M., Lommaert M.P. Characterization of a carboxypeptidase in human serum distinct from carboxypeptidase N. J. Clin. Chem. Clin. Biochem. 27:1989;277-285
3. Eaton D.L., Malloy B.E., Tsai S.P., Henzel W., Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J. Biol. Chem. 266:1991;21833-21838
4. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler. Thromb. Vasc. Biol. 20:2000;2511-2518
5. Nesheim M.E., Wang W., Boffa M., Nagashima M., Morser J., Bajzar L. Thrombin, thrombomodulin and TAFI in the molecular link between coagulation and fibrinolysis. Thromb. Haemost. 78:1997;386-391
6. Wang W., Boffa P.B., Bajzar L., Walker J.B., Nesheim M.E. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J. Biol. Chem. 273:1998;27176-27181
7. Henry M., Aubert H., Morange P.E., Nanni I., Alessi M.C., Tiret L., et al. Identification of polymorphisms in the promoter and the 3′ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood. 97:2001;2053-2058
8. Schneider M., Boffa M., Stewart R., Rahman M., Koschinsky M., Nesheim M. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme. J. Biol. Chem. 277:2002;1021-1030
9. Lau H.K., Segev A., Hegele R.A., Sparkes J.D., Teitel J.M., Chisholm R.J., et al. Thrombin-activatable fibrinolysis inhibitor (TAFI): a novel predictor of angiographic coronary restenosis. Thromb. Haemost. 60:2003;1187-1191
10. Strauss B.H., Lau H.K., Bowman K.A., Sparkes J., Chisholm R.J., Garvey M.B., et al. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation. 100:1999;1616-1622
11. Foley D.P., Escaned J., Strauss B.H., di Mario C., Haase J., Keane D., et al. Quantitative coronary angiography (QCA) in interventional cardiology: clinical application of QCA measurements. Prog. Cardiovasc. Dis. 36:1994;363-384
12. Boffa M.B., Reid T.S., Joo E., Nesheim M.E., Koschinsky M.L. Characterization of the gene encoding human TAFI (thrombin-activable fibrinolysis inhibitor; plasma procarboxypeptidase B). Biochemistry. 38:1999;6547-6558
13. Ishiwata S., Tukada T., Nakanishi S., Nishiyama S., Seki A. Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am. Heart J. 133:1997;387-392
14. Jang Y., Guzman L.A., Lincoff A.M., Gottsauner-Wolf M., Forudi F., Hart C.E., et al. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. Circulation. 92:1995;3041-3050
15. Oltrona A., Speidel C.M., Recchia D., Wickline S.A., Eisenberg P.R., Abendschein D.R. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs. Circulation. 96:1997;646-652
16. van Tilburg N.H., Rosendaal F.R., Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood. 95:2000;2855-2859
17. Silveira A., Schatteman K., Goossens F., Moor E., Scharpe S., Stromqvist M., et al. Plasma procardoxypeptidase U in men with symptomatic coronary artery disease. Thromb. Haemost. 84:2000;364-368
18. Morange P.E., Juhan-Vague I., Scarabin P.Y., Alessi M.C., Luc G., Arveiler D., et al. Association between TAFI antigen and Ala147Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thromb. Haemost. 89:2003;554-560
19. Brouwers G.J., Leebeek F.W., Tanck M.W., Wouter Jukema J., Kluft C., de Maat M.P. Association between thrombin-activatable fibrinolysis inhibitor (TAFI) and clinical outcome in patients with unstable angina pectoris. Thromb. Haemost. 90:2003;92-100
20. Tsuboi Y., Takahashi M., Ishikawa Y., Okada H., Yamada T. Elevated bradykinin and decreased carboxypeptidase R as a cause of hypotension during tryptophan column immunoabsorption therapy. Therap. Apher. 2:1998;297-299
21. Myles T., Nishimura T., Yun T.H., Nagashima M., Morser J., Patterson A.J., et al. Thrombin activatable fibrinolysis inhibitor, a potential regulator of vascular inflammation. J. Biol. Chem. 278:2003;51059-51067
22. Brouwers G.J., Vos H.L., Leebeek F.W., Bulk S., Schneider M., Boffa M., et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood. 98:2001;1992-1993
23. Guimaraes A.H.C., van Tilburg N.H., Vos H.L., Bertina R.M., Rijken D.C. Association between thrombin activatable fibrinolysis inhibitor genotype and levels in plasma: comparison of different assays. Br. J. Haematol. 124:2004;659-665